DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Blisibimod
Blisibimod
BAFF-Neutralizing Interaction of Belimumab Related to Its Therapeutic Efficacy for Treating Systemic Lupus Erythematosus
Download
Study Protocol
Rheumatology and CTD
Antagonist Antibodies Against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound S
1 the BAFF/APRIL System in SLE Pathogenesis. Fabien B Vincent1
The Future of B-Cell Activating Factor Antagonists in the Treatment of Systemic Lupus Erythematosus
Therapeutics Advisory Group
Immunfarmakológia Immunfarmakológia
(12) Patent Application Publication (10) Pub. No.: US 2013/0216742 A1 Demartino Et Al
Supplementary Material Table of Contents
NIH Public Access Author Manuscript Curr Allergy Asthma Rep
Novel Therapeutic Agents in Clinical Development for Systemic Lupus Erythematosus Natasha Jordan, Pamela MK Lutalo and David P D’Cruz*
BAFF- and APRIL-Targeted Therapy in Systemic Autoimmune Diseases Shingo Nakayamada and Yoshiya Tanaka*
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
Biologic Response Modifiers for Granulomatosis with Polyangiitis (Wegener’S): from Promise to Reality
Study Protocol Drug Substance Anifrolumab (MEDI-546) Study Code D3461C00008 Version 1.0 Date 20 Sep 2016
Top View
(INN) for Biological and Biotechnological Substances
Emerging Modes of Treatment of Iga Nephropathy
AHRQ Healthcare Horizon Scanning System – Status Update Horizon
Phase III Trial Results with Blisibimod, a Selective Inhibitor of B-Cell
Cytokine Targets in Lupus Nephritis Current and Future Prospects
Spotlight on Blisibimod and Its Potential in the Treatment of Systemic Lupus Erythematosus: Evidence to Date
A Phase II, Randomized, Double-Blind
Interferons, B Cells and Neutrophils: Innate and Adaptive Allies in Systemic Lupus Erythematosus
Variants De La Portion Fc Des Igg Cartographie Et Analyse Brevets, Confrontation Aux Biomédicaments En Développement Et Proposition D’Une Nouvelle Nomenclature
The Potential Role of Blisibimod for the Treatment of Systemic Lupus Erythematosus
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
232583426.Pdf
B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis—Role in Pathogenesis and Effect of Immunosuppressive Treatments
Spotlight on Blisibimod and Its Potential in the Treatment of Systemic Lupus Erythematosus: Evidence to Date
Report Template
IL-3Rα As a Novel Therapeutic Target in Systemic Lupus Erythematosus
B-Cell Therapy in Lupus Nephritis: an Overview
Systemic Lupus Erythematosus: a Therapeutic Challenge for the XXI Century
Reports from the Targeted Therapies Meeting 2019
1 Reduction of Anterior Uveitis Flares in Patients with Axial
(12) United States Patent (10) Patent No.: US 9,636,332 B2 Zarnitsyn Et Al
Lupus Clinical Trial Eligibility in a Real-World Setting
Patent Application Publication ( 10 ) Pub . No . : US 2018 / 0325884 A1
Nhs-England-Drugs-List-V14.1.Pdf
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
(INN) for Biological and Biotechnological Substances
( 12 ) United States Patent
Outcomes from the VALIGA Study Group in Igan
Michael H. Weisman, MD Curriculum Vitae Updated: March 25, 2021
Updates on Lupus 2017
Edition 5/14
Delamination Resistant Pharmaceutical Glass
Tenofovir Alafenamide
2016 Medicines in Development for Autoimmune Diseases
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Pbr Excluded Drugs List
Spotlight on Blisibimod and Its Potential in the Treatment of Systemic Lupus Erythematosus
E 19 October 2018
International Nonproprietary Names for Pharmaceutical Substances (INN)